Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948529 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL521857 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL996713 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL13174932 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL16004821 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL8198628 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL16004847 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL8191933 | 1.00 | TSHR (0.62) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL23539641 | 0.98 | — | — | |
| SCHEMBL409592 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912732-A | Antistatic protective glove and preparation method thereof | 山东津莱环海医疗科技有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024024624-A1 | COMPOSITION AND SLURRY, BATTERY CONSTITUENT MATERIAL USING SAME, AND ELECTRODE AND ALL-SOLID-STATE BATTERY | 株式会社日本触媒 | 2024-02-01 | — | — | WO | disclosed |
| WO-2024024628-A1 | METHOD FOR PRODUCING BATTERY CONSTITUENT MATERIAL AND ELECTRODE | 株式会社日本触媒 | 2024-02-01 | — | — | WO | disclosed |
| CN-110770959-B | Electrolyte composition, electrolyte membrane, electrode, battery, and method for evaluating electrolyte composition | 株式会社日本触媒 | 2023-08-25 | — | — | CN | disclosed |
| US-11374258-B2 | Electrolyte composition, electrolyte membrane, electrode, cell and method for evaluating electrolyte composition | NIPPON SHOKUBAI CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| EP-3648226-B1 | ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, ELECTRODE AND BATTERY | NIPPON CATALYTIC CHEM IND (JP) | 2022-06-22 | — | — | EP | disclosed |
| US-11342583-B2 | — | — | 2022-05-24 | — | — | US | disclosed |
| CN-108294973-B | Whitening skin cream | 汕头市雅蒂化妆品有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210135283-A1 | ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, ELECTRODE, CELL AND METHOD FOR EVALUATING ELECTROLYTE COMPOSITION | NIPPON SHOKUBAI CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3648226-A1 | ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, ELECTRODE, BATTERY AND METHOD FOR EVALUATING ELECTROLYTE COMPOSITION | Nippon Shokubai Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-7662773-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-02-16 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| WO-2009000752-A1 | PROCESS FOR PREPARING A DIENE COPOLYMER HAVING A POLYETHER BLOCK, REINFORCED RUBBER COMPOSITION AND TYRE | SOCIETE DE TECHNOLOGIE MICHELIN (FR) | 2008-12-31 | — | — | WO | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| WO-2006076471-A2 | BNP CONJUGATES AND METHODS OF USE | NOBEX CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005116655-A2 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2004047871-A2 | MODIFIED NATURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-0193643-A2 | Curable resin composition | KABUSHIKI KAISHA TOSHIBA (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207505-A1 | Bna Conjugates and Methods of Use | NPR1, NPPA, NPR3 | TSHR 327/4885SMN1; SMN2 368/4885ALDH1A1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.